prof. dr. Marc Peeters
- ORCID iD
- 0000-0003-4969-2303
Show
Sort by
-
High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib
-
Circulating tumor DNA detects early response to regorafenib in advanced colorectal cancer
-
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC)
-
- Journal Article
- A2
- open access
Children's International Polyposis (CHIP) study : a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis
-
- Journal Article
- A1
- open access
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer : the SIRFLOX study
-
Regorafenib assessment guided by metabolic imaging in refractory advanced colorectal cancer (aCRC) : REGARD-C study
-
Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases
-
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study
-
Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal cancer xenograft model
-
A phase II randomized study of combined infusional leucovorin sodium and 5-FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer
-
Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer
-
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study
-
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
-
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study
-
An evaluation of FDG-PET as a predictor of metabolic response to chemotherapy in metastatic colorectal cancer patients (mCRC)
-
- Miscellaneous
- open access
Assurance de qualité pour le cancer rectal : phase 3 : méthodes statistique visant à comparer les centres sur base d'un ensemble d'indicateurs de qualité
-
Assessment of tumor genotypes in metastatic colorectal cancer (MCRC): mutations beyond KRAS codons 12 and 13 as predictive biomarkers of response to panitumumab (PMAB) in a randomized, phase 3 study
-
Evaluation of panitumumab (PMAB) plus folfiri versus folfiri alone as second-line therapy in patients (PTS) with metastatic colorectal cancer (MCRC) receiving prior bevacizumab (BEV) in study 20050181
-
Panitumumab (PMAB) in combination with chemotherapy (CT) versus CT alone: health-related quality of life (HRQOL) in patients (PTS) with wild-type (WT) KRAS metastatic colorectal cancer (MCRC)
-
In vivo imaging of apoptosis in oncology : an update
-
99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab
-
- Conference Paper
- C3
- open access
Efficacy of the combined use of bevacizumab and irinotecan in a human colorectal cancer xenograft model analysed by SPECT imaging
-
- Conference Paper
- C3
- open access
FDG-PET is a predictor of metabolic response to chemotherapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Preoperative chemotherapy for colorectal liver metastases : prediction of response by DCE-MRI abd FDG-PET/CT?
-
- Conference Paper
- C3
- open access
PET as a predictor of metabolic response to antiangiogenic therapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Cystic masses of the pancreas : how useful is cyst fluid analysis in the diagnosis?
-
- Journal Article
- A2
- open access
'Doe-het-zelf chemotherapie advies' : gevaarlijke ontwikkelingen via het worldwide web
-
Familial adenomatous polyposis: clinical presentation, detection and surveillance
-
MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?
-
FDG uptake in primary squamous cell carcinoma of the head and neck : the relationship between overexpression of glucose transporters and hexokinases, tumour proliferation and apoptosis
-
Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights
-
EGFR in melanoma : clinical significance and potential therapeutic target
-
Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent
-
EUS predicts local resection for rectal cancer
-
Psychometric evaluation of the FACT colorectal cancer symptom index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness
-
Diarrhea and the rationale to use Sandostatin®
-
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer
-
EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients
-
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
-
Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation
-
In vivo toxicity and bioavailability of taxol (R) and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC
-
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
-
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma
-
KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
-
In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells
-
EUS predicts local resection for rectal cancer
-
SPECT imaging of apoptotic tumor response in a colorectal tumor model
-
- Journal Article
- A1
- open access
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
-
The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model
-
Evaluation of the treatment of peritoneal carcinomatosis of colorectal cancer (CRC) with complete cytoreduction and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicenter prospective phase II clinical study
-
- Journal Article
- A2
- open access
Haalbaarheid van een georganiseerde screening naar colorectaal carcinoom in de laag risicopopulatie
-
Low molecular weight heparin inhibits tumor associated angiogenesis in vivo
-
Mdm2 in colon carcinoma: an immunohistochemical and fluorescence in situ hybridization study
-
Low molecular weight heparin inhibits tumor associated angiogenesis in vivo
-
Defining the optimal therapy sequence in synchronous respectable liver metastases from colorectal cancers: a decision analysis approach
-
PET evaluation of anti-VEGF treatment in combination with chemotherapy in MCRC
-
Diffusion magnetic resonance imaging as surrogate marker to anti-VEGF treatment response in MCTC
-
Comparison of two contrast agents for DCE-MRI evaluation of anti-VEGF treatment in combination with chemotherapy in MCRC
-
Bevacizumab and 5-FU + Oxaliplatin or irinotecan as neoadjuvant therapy for patients with non resectable liver metastases
-
Surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis from colorectal cancer
-
MDM2 amplification in colorectal carcinomas
-
Major hepatectomies increases risk of morbidity and mortality in simultaneous resection of synchronous liver metastases and colorectal cancer
-
Similarities between total mesorectal excision for rectal cancer and total mesoduodenal excision during pancreaticoduodenectomy for adenocarcinoma of the pancreatic head: the need for effective locoregional lymfadenectomy
-
Amphiregulin and Epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with Cetuximab
-
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study
-
Association of Progression-free Survival, Overall Survival, and Patient-reported Outcomes by Skin Toxicity and KRAS Status in Patients Receiving Panitumumab Monotherapy
-
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study
-
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy
-
Yttrium-90 labelled resin microspheres for treatment of primary and secondary malignant liver tumors
-
FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases
-
Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma
-
Forcing cancer cells to commit suicide
-
Combined effect of EPO and radiotherapy on the expression of endogenous molecular markers of tumor metabolism and metastasis
-
The potential role of targeted therapies in the management of neuroendocrine tumours
-
The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
-
Role of chemotherapy in gastro-entero-pancreatic neuroendocrine tumors: the end of a story?
-
The role of surgery and transplantation in neuroendocrine tumours
-
Carcinoid heart disease: a hidden complication of neuroendocrine tumours
-
Diagnostic pitfalls in digestive neuroendocrine tumours
-
Quality assurance and recommendations for quality assessment of screening colonoscopy in Belgium.
-
Three-year survival result of CORE (Capecitabine, Oxaliplatin, Radiotherapy and Excision) study after post-operative chemotherapy in patients with locally advanced rectal adenocarcinoma
(2009) -
A phase 1 B/2 trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): safety results.
(2009) -
Alles over de uitbreiding van de indicatie voor capecitabine (Xeloda)
-
Locoregional and radioisotopic targeted treatment of neuroendocrine tumours
-
Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
-
- Journal Article
- A1
- open access
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer : a multicentre two-part phase I/II study
-
In vitro cytotoxicity of paclitaxel/β-cyclodextrin complexes for HIPEC
-
Gene expression differentiates liver metastases from isolated peritoneal metastases in colorectal cancer
-
Microsatellite instability in Belgian sporadic colon carcinomas has no independent prognostic value in a Belgian study population
-
Advances in the management of gastrointestinal stromal tumours
-
Expression of SGLT1 and Bcl-2 in pancreatic cancer and their metastases related to survival
-
Effects of the low molecular weight heparin nadroparin on tumor associated angiogenesis
-
EFFECTS OF THE LOW MOLECULAR WEIGHT HEPARIN NADROPARIN ON TUMOR ASSOCIATED ANGIOGENESIS
-
The role of oral fluoropyrimidines in the treatment of advanced gastric cancer
-
Molecular imaging of tumor associated angiogenesis uzing P1127, a novel MRI contrast agent targeting alfa V beta 3 integrin
(2008) -
Health-related quality of life (HRQOL) and colorectal cancer (CRC) symptoms in metastatic CRC: panitumumab plus best supportive care (BSC) vs. BSC alone by kras tumor status.
-
DUSP4 expression level in colorectal primaries predicts overall survival benefit in Kras wild-type and Kras mutant colorectal cancer after treatment with cetuximab for metastatic disease.
-
Amphiregulin and Epiregulin expression in primary colorectal cancer identifies a subgroup of patients that will respond to EGFR inhibition.
-
COST-EFFECTIVENESS OF PANITUMUMAB PLUS BEST SUPPORTIVE CARE (BSC) COMPARED WITH BSC ALONE IN CHEMOREFRACTORY METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH WILD-TYPE (WT) KRAS TUMOR STATUS IN THE NETHERLANDS